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MelanomaAs an ideal tumor antigen, survivin has been widely used for tumor immunotherapy. Nevertheless, no effec-
tive protein vaccine targeting survivin has been reported, which may be due to its poor ability to induce cel-
lular immunity. Thus, a suitable immunoadjuvant and optimized immunization strategy can greatly enhance
the cellular immune response to this protein vaccine. DDA/MPL (monophosphoryl lipid A formulated with
cationic dimethyldioctadecylammonium) has been reported to enhance the antigen uptake and presentation
to T cells as an adjuvant. Meanwhile, a heterologous prime-boost strategy can enhance the cellular immunity
of a protein vaccine by applying different antigen-presenting systems. Here, DDA/MPL and an adenovirus
prime-protein boost strategy were applied to enhance the speciﬁc anti-tumor immunity of a truncated
survivin protein vaccine. Antigen-speciﬁc IFN-γ-secreting T cells were increased by 10-fold, and cytotoxic T
lympohocytes (CTLs) were induced effectively when the protein vaccine was combined with the DDA/MPL
adjuvant. Meanwhile, the Th1 type cellular immune response was strongly enhanced and tumor inhibition
was signiﬁcantly increased by 96% with the adenovirus/protein prime-boost strategy, compared to the pro-
tein homologous prime-boost strategy. Moreover, this adjuvanted heterologous prime-boost strategy com-
bined with oxaliplatin could signiﬁcantly enhance the efﬁciency of tumor growth inhibition through
promoting the proliferation of splenocytes. Thus, our results provide a novel vaccine strategy for cancer ther-
apy using an adenovirus prime-protein boost strategy in a murine melanoma model, and its combination
with oxaliplatin may further enhance the anti-tumor efﬁcacy while alleviating side effects of the drug.
Crown Copyright © 2013 Published by Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Survivin, a member of the inhibitor of apoptosis (IAP) family, is
broadly expressed in several types of human cancers and embryonic tis-
sues. However, it is mostly absent in differentiated cells [1,2]. Survivin
expression is correlated with chemoresistance, unfavorable prognosis
and shortened patient survival [3]. These characteristics render it an
ideal target for cancer immunotherapy. Presently, many vaccines
targeting survivin are being evaluated both in pre-clinical and clinical
trials. A modiﬁed vaccinia Ankara expressing survivin combined with
gemcitabine has been reported to generate speciﬁc anti-tumor effects
in a murine pancreatic carcinomamodel [4]. A survivin peptide vaccine
was shown to elicit therapeutic effects with a T helper cell supportedx: +86 431 85167823.
eikong@jlu.edu.cn (W. Kong).
ier B.V. Open access under CC BY-NC-cytotoxic T lymphocyte (CTL) responses againstmurine cerebral glioma
[5]. In clinical trials, a human leukocyte antigen (HLA)-A24-restricted
antigenic peptide, survivin-2B80-88, showed enhanced immunogenicity
and clinical effects in advanced colorectal cancer patients [6]. In another
study of metastatic renal cell carcinoma patients vaccinated with den-
dritic cells (DCs) loaded with survivin peptides, disease stabilization
was achieved in approximately half of the cases, and the effect persisted
for at least 6 months in more than 1/3 of the patients [7].
Research on protein-based vaccines against cancer has been carried
out for many years. However, there are still no reports of an effective
protein-based vaccine targeting survivin, perhaps due to the fact that
protein vaccines generally induce relatively stronger levels of humoral
immunity than cellular immunity, while the latter is considered essen-
tial for tumor immunotherapy. Therefore, an effective immunoadjuvant
and improved strategy is needed for successful induction of cellular im-
mune responses against the survivin protein vaccine [8].
Immunoadjuvants such as CpG ODN [9], incomplete Freund's ad-
juvant [6], aluminum hydroxide [Al(OH)3] [10] and monophosphoryl
lipid A (MPL) [11] have been used to enhance responses to a variety
of vaccines. Among these, Al(OH)3, which can effectively induce TND license.
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approved for clinical trials [12,13]. MPL activates Toll-like receptor 4
(TLR4) and triggers the Trif-dependent pathway [14]. Moreover,
MPL is licensed for vaccines against human papillomavirus types 16
and 18 (Cervarix GSK) and hepatitis B virus (Fendrix GSK). DDA
(dimethyldioctadecylammonium bromide) is a cationic liposome
that is able to enhance antigen uptake and presentation [15]. Al-
though MPL formulated with DDA liposomes (DDA/MPL) is not ap-
proved for clinical trials as an adjuvant, it has been shown to induce
a signiﬁcant level of protective immunity in Chlamydia and tubercu-
losis vaccine research [16,17]. However, whether DDA/MPL can en-
hance the efﬁcacy of tumor vaccines has not been reported. Thus,
DDA/MPL was selected as an adjuvant for the survivin-based protein
vaccine to evaluate its ability to enhance anti-tumor immunity in our
study. Due to safety concerns of full-length survivin, an anti-apoptosis
protein, this vaccine was based on a truncated form of survivin (S8)
with a deletion of seven amino acids at its N-terminus, which was
shown to be non-functional in our previous study [18].
In order to enhance the cellular immune responses to a vaccine, it is
necessary to select an appropriate adjuvant and optimized vaccine
strategy. Heterologous prime-boost immunization strategies have
been reported to increase the number of speciﬁc T cells and the efﬁcien-
cy of CTLs [19], enhance Th1 type cellular immunity [20] and strengthen
anti-tumor effects [21,22]. Moreover, it has been shown to be more im-
munogenic than homologous prime-boost in many cases, in studies of
vaccines against HIV-1 [23,24] or other pathogens [25,26] and cancer
vaccines [27]. Among the heterologous prime-boost strategies, vector
prime-protein boost has been widely applied with HIV-1 vaccines
[28,29], but seldom used in cancer vaccines [30,31].
The purpose of our studywas to evaluatewhether the S8 protein vac-
cine can induce cellular immune responses and anti-tumor effects
through the optimization of immune adjuvant and immunization strate-
gies. The immunogenicity and anti-tumor effects of a recombinant ade-
novirus prime-protein plus adjuvant boost strategy were compared
with those of a homologous protein prime-boost and a protein prime-
recombinant adenovirus boost strategy. Due to the heterogeneity of
tumor cells and complexity of tumor microenvironments, many clinical
trial studies of tumor vaccines alone have failed. As the administration
of other therapies along with a vaccine may enhance its efﬁcacy, the
tumor inhibitory effect of our cancer vaccinewas also tested in combina-
tion with a widely used anti-tumor chemotherapy drug oxaliplatin.
2. Material and methods
2.1. Establishment of a stable cell line expressing full-length human
survivin
The human survivin gene fragment from the VR1012-survivin plas-
midmaintained byour laboratorywas cloned into pEGFP-N3 (Invitrogen)
using Sal I and BamH I restriction enzymes, generating pEGFP-N3-
survivin. This resulting plasmid was transfected into B16 cells using
LipofectamineTM 2000 (Invitrogen). After selection by G418 (Invitrogen),
a cell clone expressing a relatively weak green ﬂuorescent protein (GFP)
signal, simulating a physiological level of expression, was ampliﬁed in
culture. Finally, survivin expression in the stable cell line (Sf+ B16) was
conﬁrmed by quantitative real-time reverse-transcriptase (RT) PCR
(qRT-PCR) using primers 5′-CCACCGCATCTCTACATTC A-3′ and 5′-TATG
TTCCTCTATGGGGTCG-3′ and by Western blot using an anti-mouse
survivin monoclonal antibody (Gene Tex).
2.2. qRT-PCR
RNA was extracted by the guanidine isothiocyanate and chloroform
method (Invitrogen) from the Sf+ B16 and B16 cells. All RNA samples
were treated with DNase I (Promega). For all samples, 1 μg of total
RNAwasused to synthesizeﬁrst-strand cDNAwith reverse transcriptase(Invitrogen) and random primers. The cDNA synthesis was performed
at 37 °C for 60 min after heat inactivation at 95 °C for 10 min. PCR
was performed using 1× SYBR Green PCR Master Mix (Transgen) on a
real-time PCR system (CFX96; BioRad). Cycling conditions were as
follows: 2 min at 50 °C, 10 min at 95 °C, and 40 cycles of 15 s at 95 °C,
plus 1 min at 60 °C. Commercial software (CFX Manager) was used to
calculate relative survivin expression normalized to the β-actin endoge-
nous control for all genes studied using the 2−ΔΔCt method.
2.3. Mice and murine melanoma model
Speciﬁc pathogen-free six-week-old female C57BL/6micewere pur-
chased from the Beijing Laboratory Animal Center and housed in appro-
priate animal care facilities during the experimental period. They were
handled following the international guidelines required for experimen-
tation with animals. All animal studies were approved by the Commit-
tee on the Use and Care of Animals of Jilin University. The C57BL/6
mice were challenged subcutaneously with 1 × 105 Sf+ B16 viable
cells in the right lower ﬂank and monitored daily for tumor develop-
ment. Tumor width and length were measured periodically with a cali-
per and estimated using the formula: (length × width2) / 2 (mm3).
Tumors ≥ 2 mm in diameter with progressive growth were recorded
as positive.
2.4. Recombinant protein, recombinant adenovirus and immunization
schedule
The recombinant full-length human survivin and adenovirus 5 vec-
tor expressing the truncated survivin protein (AD-S8)were prepared as
previously described [18,32]. Brieﬂy, the sequence encoding S8 was
obtained by PCR using the plasmid pRSET-B-survivin as a template
and then subcloned into the prokaryotic vector pRSET-B (Invitrogen)
for S8 protein expression. Expression of the recombinant protein was
conﬁrmed by immunoblotting using a mouse monoclonal antibody
(Gene Tex).
S8 recombinant protein (50 μg), 100 μg Al(OH)3 (Sigma) or 250 μg
DDA (Arcos Organics) plus 25 μg MPL (Avanti Polar Lipids) were
injected separately or as a mixture subcutaneously in C57BL/6 mice
(5 mice per group). AD-S8 (1 × 108 pfu) was injected intramuscularly
into the tibialis anterior muscles of both hind legs (50 μl each). The ho-
mologous prime-boost strategy was carried out by immunizing the
mice with S8 + DDA/MPL (S8 pro) three times at 2-week intervals.
Two different heterologous prime-boost regimens were tested: one by
giving S8 pro for the ﬁrst two times, followed by AD-S8 for the last
time; the other was by giving AD-S8 for the ﬁrst time, followed by S8
pro for the last two times (with 2-week intervals between all immuni-
zations). Two weeks after the ﬁnal immunization, all mice were
sacriﬁced to detect cellular immune responses in splenocytes.
2.5. IFN-γ ELISPOT assay
Antigen-speciﬁc release of IFN-γ from effector T cells was assessed
with an ELISPOT kit (BD Biosciences) according to the instructions
provided by the manufacturer. The reaction was terminated upon
the appearance of dark purple spots, which were quantitated using
the AlphaImager System.
2.6. In vitro cytotoxicity assay
In vitro cytotoxicity was determined as previously reported [33].
B16 cells (1 × 106 cells/ml) used as target cells were pulsed with or
without 5 μg/ml of the MHC-I H-2Db restricted survivin peptide
(STFKNWPFL 20–28) [34,35] in RPMI-1640 medium containing 10%
fetal bovine serum (FBS) for 2 h at 37 °C. Meanwhile, an unrelated pep-
tide (SAPDTRPAP, derived from another tumor-associated antigen
MUC1) was used as a control. Peptide-loaded B16 cells were then
Fig. 1. Production of recombinant human truncated survivin. (A) Schematic represen-
tation of pRSET-B expression vector with human S8 cDNA. (B) Puriﬁcation of survivin
protein from cell lysates as assessed by SDS-PAGE gels stained with Coomassie Blue.
(C) Veriﬁcation of puriﬁed protein by Western blot.
Fig. 2. Establishment of the stablemelanoma (B16)-cell line expressing survivin. (A) Stan-
dardized gene expression ratio in Sf+ B16 and B16 cells using qRT-PCR. (B) Expression of
survivin protein in Sf+ B16 and B16 cells by Western blot using a survivin monoclonal
antibody.
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cent dye (5 μM) in RPMI-1640 medium without FBS for 10 min, while
unloaded B16 cells were labeled only with CFSE (0.5 μM). CFSE labeling
was stopped by the addition of an equal volume of cold FBS for 3 min, and
then the cells were washed and counted. CFSEhigh- and CFSElow-labeled
cellsweremixed together at a 1:1 ratio and conﬁrmed byﬂow cytometry.
Different numbers of splenocytes from vaccinated mice were then incu-
bated with 5 × 104 of the peptide-loaded or unloaded B16 cells for 8 h
at 37 °C, after which the co-cultures were analyzed on a FACS MoFlo
XDP (Beckman Coulter) for the percentage of CFSE-labeled B16 cells. Spe-
ciﬁc killing was calculated as follows: % killing = [1-(peptide-loaded
cells/unloaded cells from immunized group)/(peptide-loaded cells/
unloaded cells from naive group)] × 100.
2.7. Determination of activated CD8+CD69+ T cells by ﬂow cytometry
The percentage of activated CD8+CD69+ T cells from freshly isolat-
ed splenocytes was determined by a standard protocol. Splenocytes
(1 × 107) were stimulated with survivin protein diluted with RPMI-
1640medium at a concentration of 5 μg/ml for 15 h at 37 °C and then in-
cubated with anti-CD8-APC and anti-CD69-PE antibodies (eBioscience)
on ice in the dark for 15 min. Samples were washed twice with staining
buffer and then analyzed by FACS.
2.8. Tumor immunotherapy in C57BL/6 mice
C57BL/6 mice (10 per group) were injected subcutaneously with
1 × 105 Sf+ B16 viable cells per mouse on day 0. After the tumors
were established, mice in the vaccine group were immunized
according to different prime-boost strategies as described above on
days 3, 10 and 17. Negative control mice were given 100 μl PBS. In
addition, oxaliplatin was injected intraperitoneally every four days(0.1 mg/50 μl per mouse each time) as a positive control. The combi-
nation group was immunized with the vaccine and treated with
oxaliplatin simultaneously. Tumor diameters were measured in two
dimensions every 2 days. Tumor volumes were calculated as de-
scribed above. Mice were sacriﬁced at week 4 after inoculation with
Sf+ B16 cells, and the tumors were removed and weighed.
2.9. Cytokine detection by multiplex ﬂow immunoassay
Splenocytes (1 × 107) from vaccinated tumor-bearing mice were
stimulated with the full-length survivin protein at a concentration
of 5 μg/ml for 15 h, and then the cell culture supernatants were col-
lected to measure multiple cytokines. Th1 (IFN-γ and IL-2) and Th2
(IL-4, and IL-10) cytokines were detected by Bio-Plex pro assays.
After the Bio-Plex beads were incubated with the cell culture super-
natants in a reaction vessel for half an hour at room temperature in
the dark, they were washed, and a ﬂuorescent reporter antibody
was added to the reaction mixture. Following the second incubation
of approximately 40 min and a wash cycle, the beads were suspended
in buffer and passed through a ﬂow-based detector. Results were cal-
culated as median ﬂuorescence intensity (MFI) units.
2.10. Mouse Ig isotyping
Sera from tumor-challenged mice were tested for speciﬁc Ig subclass
antibodies using the mouse immunoglobulin screening/isotyping kit
(Southern Biotech). In brief, a 96-well ﬂat bottommicroplate was coated
with 0.25 μg/well of full-length survivin protein, diluted in PBS and
incubated overnight at 4 °C. The plate was blocked with 100 μL PBS
containing 3% bovine serum albumin (BSA) for 1 h at 37 °C. Serumdilut-
ed 1:100 dilution in 1%PBSwas added to eachwell (100 μL) and incubat-
ed for 2 h at 37 °C. The plate was then incubated with 100 μL of subclass
speciﬁc antibodies diluted at 1:2000 for 30 min at room temperature.
The enzyme reactionwas developedwith 3,3′,5,5′-tetramethylbenzidine
(TMB) for 10–15 min and stoppedwith 2 MH2SO4. Optical density (OD)
was determined with a microplate reader at a wavelength of 450 nm.
2.11. Cell proliferation assay
Single cell suspensions of splenocytes at 2 × 106/ml in PBS were
mixed with an equal volume of 20 mM CFSE in PBS (Molecular
Probes). Cells were incubated for 10 min at room temperature in
the dark. Labeling was stopped by addition of FBS, and cells were
washed twice with PBS. CFSE-labeled spleen cells were cultured at
37 °C for 5 days and then analyzed by ﬂow cytometry.
2.12. Statistical analyses
All in vivo and in vitro experiments were performed at least 3 times.
Data were analyzed using one-way ANOVA. Differences between the
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T-test. P b 0.05 was considered signiﬁcant, and P b 0.01 was considered
highly signiﬁcant. All statistical analyseswere performedwith Graphpad
Prism software.
3. Results
3.1. Production of recombinant S8 protein and generation of stable
Sf
+B16 cells
After cloning the gene (Fig. 1A), the recombinant S8 protein was
expressed in Escherichia coli. The recombinant S8 protein could be specif-
ically induced by IPTG, and its purity after passing through a Ni-NTA
resin column was over 90% as determined by densitometry analysis
with BandScan 5.0 software (Fig. 1B). The puriﬁed protein was con-
ﬁrmed by immunoblotting using amousemonoclonal antibody (Fig. 1C).
For testing the anti-tumor immune response of vaccines against
melanoma, a B16 stable cell line expressing a weak or near physiolog-
ical level of human survivin was established. The mRNA levels of
human and mouse survivin in Sf+B16 and wild-type B16 cells were
veriﬁed by real-time PCR (Fig. 2A), and survivin protein level was ver-
iﬁed by Western blot (Fig. 2B). Sf+B16 showed nearly 4-fold higherFig. 3. Comparison of DDA/MPL and Al(OH)3 as adjuvants for the S8 protein vaccine. (A) Immu
sacriﬁced 2 weeks after the last immunization. (B) Splenocytes from vaccinatedmicewere stim
measured by ELISPOT. Left, mean number of IFN-γ spots per 1 × 106 cells from individually te
S8 + DDA/MPL group (C) In vitro CTL assay of mouse splenocytes against B16 cells pulsed witmRNA and protein levels compared to wild-type B16, indicating
that the stable Sf+B16 cells had been generated successfully.
3.2. DDA/MPL more strongly enhances cellular immune responses than
Al(OH)3 as an adjuvant to the S8 protein vaccine
To compare adjuvant effects of Al(OH)3 and DDA/MPL with the S8
protein vaccine, groups of mice were immunized with S8 + DDA/
MPL, S8 + Al(OH)3 or S8 as shown in Fig. 3A. The results showed that
both adjuvants increased the frequencies of antigen-speciﬁc IFN-γ-
secreting T cells as detected in an ELISPOT assay, and the antigen-
speciﬁc response in mice vaccinated with S8 pro was signiﬁcantly
(nearly 2-fold) higher than that observed in mice given S8 protein
and Al(OH)3 (Fig. 3B). Moreover, antigen-speciﬁc cytotoxicity was
also assessed for the different groups (Fig. 3C). Mice vaccinated with
S8 + DDA/MPL showed strong cytotoxic activity when the target cells
B16 were pulsed with the survivin peptide (STFKNWPFL). Similar re-
sults were obtained when Sf+ B16 cells were utilized as the target cells
(data not shown). No speciﬁc cytotoxicity was observed against B16
cells labeled with an unrelated peptide derived from another tumor-
associated antigen MUC1 as a control. Moreover, the mean number
of unstimulated splenocytes secreting IFN-γ in the S8 + DDA/MPLnization schedule. Mice were immunized three times at 2-week intervals. The mice were
ulatedwith full-length survivin protein, and the frequency of IFN-γ-producing T cells was
sted mice ± SD (*P b 0.05; **P b 0.01; ns, not signiﬁcant). Right, ELISPOT analysis of the
h a survivin peptide (STFKNWPFL) or an unrelated peptide (SAPDTRPAP) as target cells.
Fig. 4. Cellular responses to homologous or heterologous vaccinations in non-tumor bearing mice. (A) C57BL/6 mice were injected with PBS, AD-S8 intramuscularly or S8 pro subcutane-
ously at 2-week intervals. (B) Splenocytes from vaccinated mice were stimulated with full-length survivin protein, and the frequencies of IFN-γ-producing T cells were measured by
ELISPOT. (C) Representative histograms showing activated CD8+ T cells. Relative proportions of CD8+CD69+ cells are indicated. Live lymphocytes were gated by forward
scatter (FSC) and side scatter (SSC), and then the CD8+CD69+ cells were analyzed. (D) Cytolytic activity of splenocytes from immunized mice was determined by measur-
ing speciﬁc killing of survivin20-28-pulsed target cells (CFSE high) relative to control non-pulsed target cells (CFSE low). E:T ratio = ratio of effecter cells to target cells.
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group, suggesting the greater enhancement of effector T cell immunity
for the S8 protein vaccine by the DDA/MPL adjuvant relative to Al(OH)3.
3.3. Prime-boost immunization signiﬁcantly enhances cellular immunity
To compare the efﬁcacy of heterologous versus homologous prime-
boost vaccination, various immunization schemes were employed. The
heterologous prime-boost vaccination of mice was carried out at
2-week intervals with two protocols: one involved two subcutaneous
injectionswith S8 pro, followed by AD-S8, while the other one included
one injection with AD-S8, followed by two S8 pro subcutaneous injec-
tions (Fig. 4A). Mice were sacriﬁced 2 weeks after the last immuniza-
tion, and their isolated splenocytes were assessed by the ELISPOT
assay, ﬂow cytometric analysis and cytotoxicity assay. The results
showed that all immunization groups could enhance cellular immunity
(P b 0.01), including the single adenovirus immunization. Moreover,
both heterologous prime-boost immunization strategies induced simi-
lar frequencies of survivin-speciﬁc IFN-γ-releasing T cells (Fig. 4B), acti-
vated CD8+ T cells (Fig. 4C) and speciﬁc cytotoxicity, compare with
those of the homologous immunization strategy (Fig. 4D) (P > 0.05).
Meanwhile, these measures of cellular immunity were signiﬁcantly
higher (2–3-fold) than those obtained with AD-S8 immunization
alone (*P b 0.05; **P b 0.01) (Fig. 4B.C).
3.4. AD-S8 prime-S8 pro boost vaccine regimen enhances anti-tumor
effects
To evaluate whether the three different prime-boost regimens have
similar inhibitory effects on tumor growth, C57BL/6 mice (10 per
group) were inoculated with Sf+ B16 cells (1 × 105) on day 0. After
tumor establishment, the mice were immunized with PBS, S8 pro, S8
pro/AD-S8 or AD-S8/S8 pro on days 3, 10 and 17. Tumor growth was
monitored for 28 days after inoculation. As shown in Fig. 5A, tumorgrowth was potently inhibited in mice vaccinated with heterologous
prime-boost regimens relative to those immunized with PBS or S8 pro
alone (*P b 0.01; **P b 0.05). Moreover, tumors were signiﬁcantly
inhibited in mice primed with AD-S8 and boosted with S8 pro, com-
pared to those primed with S8 pro and boosted with AD-S8
(P b 0.05). Based on tumorweights (Fig. 5B), the AD-S8/S8 pro strategy
showed a tumor inhibition ratio of 125% relative to the PBS group,
versus 14% for the S8 pro group and 52% for the S8 pro/AD-S8 group.
The tumor inhibition by the adenovirus prime-protein boost strategy
increased by 96%, compared to that of the homologous protein prime-
boost strategy. To investigate the anti-tumormechanism of the vaccine,
cytokines, isotypes of survivin-speciﬁc antibodies and survivin-speciﬁc
cytotoxicity were evaluated. In addition, Th1 (IFN-γ and IL-2) and Th2
(IL-4 and IL-10) cytokines were detected simultaneously using the
BioPlex™ 2200 System (Fig. 5C). Splenocytes from challenged mice
were cultured in the presence of survivin protein, and the cytokines
were detected in the supernatants. Nearly all of the cytokines tested
(expressed inMFI units)were increased signiﬁcantly in the supernatant
of splenocytes from the immunized groups but not the PBS control
group after stimulation with survivin protein. The IL-2 level was
20-fold higher in the S8 protein vaccinated group than that of the PBS
negative group. Moreover, the IL-2 elicited by AD-S8/S8 pro was almost
60 times higher than that of the PBS group. The MFI levels of
antigen-speciﬁc IFN-γ and IL-10 were 2–4 times higher than those of
the negative group. While the survivin-speciﬁc IL-4 level was also sig-
niﬁcantly higher (2–4-fold) than the PBS group, it was almost the
same among the three vaccination groups. These results suggested
that the vaccines, especially the AD-S8/S8 pro protocol, could induce
IL-2 as the dominant cytokine indicative of a Th1 type biased immune
response in tumor-challenged mice. We further investigated the in
vivo effects of AD-S8/S8 pro on the modulation of antigen-speciﬁc anti-
body responses by favoring the development of Th1 versus Th2 cells. As
shown in Fig. 5D,mice vaccinatedwith AD-S8/S8pro presented a higher
IgG2a/IgG1 ratio than that of other groups (P b 0.05). Thus, the AD-S8
Fig. 5. Growth inhibition of survivin-expressing tumors by therapeutic immunization ofmicewith AD-S8/S8 pro. Female C57BL/6mice were inoculatedwith 1 × 105 Sf+ B16 cells on day
0, and treated on days 3, 10 and 17 (n = 10). The tumor volume (A)wasmeasured for 28 days after tumor challenge. The tumorweights (B) weremeasured on day 28 after tumor chal-
lenge. PBS group = 6.96 ± 1.20 g; S8 pro group = 6.07 ± 1.17 g; S8 pro/AD-S8 group = 4.59 ± 0.70 g; AD-S8/S8 pro group = 3.09 ± 0.59 g; (*P b 0.05; **P b 0.01; ns, not signiﬁ-
cant). (C–E)Micewere sacriﬁced 28 days after tumor challenge to conduct serum Ig isotyping and proﬁling of cytokines released from splenocytes of vaccinated tumor-bearingmicewith
or without in vitro stimulation by survivin protein. (C) Multiple cytokines were measured using the BioPlex™ 2200 System. Vaccination with AD-S8/S8 pro elicited signiﬁcant levels of
antigen-speciﬁc splenocytes secreting both Th1 and Th2 cytokines. Unstimulated, splenocytes incubatedwith RPMI-1640; stimulated, splenocytes incubatedwith survivin protein. (D) Rel-
ative values of IgG1 and IgG2a and the ratio of IgG2a/IgG1 are shown. Serum was collected when the mice were sacriﬁced; IgG1 and IgG2a were detected by ELISA. (E) In vitro CTL assays
using B16 cells pulsed by a survivin peptide (STFKNWPFL) as target cells.
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Moreover, the antigen-speciﬁc CTL activity in splenocytes of AD-S8/S8
pro vaccinated mice was most enhanced compared to other groups
(P b 0.05) (Fig. 5E), while it was similar among the two other immu-
nized groups and the PBS group (P > 0.05).
3.5. Synergistic effects of S8-based vaccine combined with oxaliplatin in
tumor therapy
Finally, we determinedwhether the S8-based vaccine and oxaliplatin
could produce synergistic effects in tumor therapy. As a positive control,
mice were treated with oxaliplatin every four days for four times from
day 3 and then sacriﬁced on day 28 after tumor challenge. As shown in
Fig. 6A, the vaccinewith the adjuvant group decreased the tumorweight
by 125% compared with the PBS group, while chemotherapy alone de-
creased it by 88%. Moreover, the efﬁcacy of the vaccine administered
therapeutically was enhanced by nearly 350% when combined with
oxaliplatin. Meanwhile, there was a statistically signiﬁcant difference in
tumor volumes between the AD-S8/S8 pro/Oxa and oxaliplatin as wellas AD-S8/S8 pro groups (*P b 0.01; **P b 0.05) (Fig. 6B). Furthermore,
compared to the PBS control, the capability of AD-S8/S8 pro in pro-
moting lymphocyte proliferation was increased by nearly 2-fold,
while that of AD-S8/S8 pro combined with oxaliplatin was elevated
by nearly 3-fold. The combination treatment resulted in 2-fold
higher proliferation of lymphocytes than with each component sep-
arately (Fig. 6C). Therefore, oxaliplatin may help to improve the out-
come of survivin-based immunotherapy.
3.6. Safety
To evaluate the toxicity of the different immunization regimens,
livers and kidneys from vaccinated mice were removed and stained
by hematoxylin-eosin (Fig. 6D). We found no signiﬁcant difference
in the hepatic sinusoid and lobular architecture of livers nor in the
morphologic structure of kidneys. There was also no disturbance in
the body weights of mice immunized with AD-S8/S8 pro (P > 0.05)
(Fig. 6E). Moreover, the vaccine also alleviated side effects of the che-
motherapy drug oxaliplatin, such as emaciation and poor activity.
Fig. 6. Anti-tumor effects of the survivin-based vaccine combined with oxaliplatin. Sf+ B16 cells were inoculated into C57BL/6 mice on day 0. After the tumor model was
established, the vaccine was given three times at 1-week interval starting on day 3. The oxaliplatin group received treatment with the drug every 4 days. Mice were sacriﬁced
on day 28. (A) Tumor volumes were measured every other day until day 28 (n = 10). Compared to either the immunotherapy group or oxaliplatin group, the combination could
inhibit tumor growth effectively (*P b 0.05; **P b 0.01; ***P b 0.001; ns, not signiﬁcant). (B) On the 28th day after tumor challenge, mice were sacriﬁced to measure tumor
weights. PBS group = 6.96 ± 1.20 g; oxaliplatin group = 3.68 ± 0.56 g; AD-S8/S8 pro group = 3.09 ± 0.59 g; AD-S8/S8 pro/oxa group = 1.60 ± 0.33 g; (*P b 0.05;
**P b 0.01; ***P b 0.001; ns, not signiﬁcant). (C) After isolation, splenocytes were labeled with 10 μM CFSE. Cell proliferation was evaluated by ﬂow cytometry after incubation
for 5 days. (D) Liver and kidneys from vaccinatedmice were stained with hematoxylin-eosin for assessment of toxicity. (E) Body weights of mice immunized with PBS, AD-S8/S8
pro, oxaliplatin or AD-S8/S8 pro/oxa (n = 10).
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As a member of the inhibitor of apoptosis protein (IAP) family,
survivin is an attractive target for cancer vaccines and immunotherapy.
Indeed, many reports have investigated the feasibility and efﬁcacy of
targeting this antigen in different types of cancer vaccines. However,
due to the poor induction of cellular immunity, no effective protein vac-
cine targeting survivin has been reported thus far. Therefore, an appro-
priate adjuvant and optimized immunity strategy were tested in this
study in order to enhance the cellular immunity of a truncated survivin
protein (S8), selected as the immunogen to avoid the potential anti-
apoptosis function of full-length survivin.
At present, there are several survivin vaccines in clinical trials, mainly
DC and peptide-based vaccines, which can elicit immune responses ef-
fectively but can only reduce the tumor volume slightly [36]. Moreover,peptide vaccines generally have a single or few antigenic sites and low
stability, while antigen-loaded DC vaccines are difﬁcult to prepare, limit-
ing the development of these approaches. Therefore, protein vaccines
may be a useful strategy for cancer immunotherapy, since they offer di-
verse antigenic sites and are relatively convenient to produce. However,
the propensity of protein-based vaccines to favor the induction of
humoral immunity over cellular immunity, the latter of which is consid-
ered to be critical for cancer immunotherapy, necessitates having an
immunoadjuvant to enhance the cellular responses. In the present
study, the comparative analysis of Al(OH)3 and DDA/MPL showed that
they elicited similar levels of humoral immune responses when com-
bined with the S8 protein (data not shown). However, administration
of the S8 protein plus DDA/MPL induced a 2-fold higher frequency of
antigen-speciﬁc IFN-γ-producing T cells and stronger survivin-speciﬁc
cytotoxicity than in the S8 + Al(OH)3 group (Fig. 3B, C). Therefore, the
16 Y.-Q. Wang et al. / International Immunopharmacology 17 (2013) 9–17DDA/MPL adjuvant was used for further studies as it could enhance cel-
lular immunity of S8 protein more effectively.
In addition to selecting an appropriate adjuvant for the S8 protein
vaccine, the immunization strategy was another factor considered in
this study. A successful vaccine usually requiresmore than one immuni-
zation, or a prime-boost regimen, to effectively induce a protective/
therapeutic immune response [37]. Here, both homologous and heter-
ologous prime-boost immununization strategies were shown to induce
antigen-speciﬁc cellular immunity (Fig. 4), but only the heterologous
prime-boost regimens could inhibit tumor growth in the melanoma
mouse model (Fig. 5A, B). Moreover, the AD-S8 prime-S8 pro boost
strategy showed better efﬁcacy than the S8 pro prime-AD-S8 boost
strategy (P b 0.05) in the reduction of tumor volume and weight.
These resultsmay be attributed to the enhancement of T cellular immu-
nity by the immunization. Thus, vaccinationwith AD-S8/S8 pro not only
enhanced the ratio of IgG2a/IgG1 signiﬁcantly (Fig. 5D), but it also
greatly increased the production of the Th1 cytokine IL-2 while weakly
improving the Th2 cytokines IL-4 and IL-10 (Fig. 5C). In addition, vacci-
nation with AD-S8/S8 pro strongly enhanced the cytotoxicity of speciﬁc
tumor killer T lymphocytes (Fig. 5E); however, other groups failed to
activate CTLs in melanoma-bearing mice. The ability to induce strong
immune responses, especially robust CTL responses, is needed for effec-
tive anti-tumor activity [38]. However, many factors impede vaccine-
mediated elicitation of CTL responses in tumor-bearing mice, such as
the down-regulation of MHC-I molecules, co-stimulatory factors and
adhesion molecules in tumor cells, and the dysfunction of DC cells,
which are the main antigen-presenting cells, in tumor-bearing mice
[39]. Recombinant adenovirus has been shown to enhance the
immunostimulatory capacity of DCs through the up-regulation of
co-stimulatory molecules CD80, CD86 and CD40 and the major histo-
compatibility complex class I and II molecules [40]. In this study,
AD-S8 was injected in the S8 pro/Ad-S8 group on day 17 after tumor
challenge when the tumor-bearing mice were overwhelmed with
DC-mediated immune activation, compromising their ability to mount
an effective and speciﬁc booster response to survivin.Moreover, the rel-
atively lower levels of CTL activities of the S8 pro and S8 pro/AD-S8
groups were consistent with the observed weaker anti-tumor effects.
Taken together, the AD-S8/S8 pro immunization strategy resulted in en-
hanced anti-tumor efﬁcacy, which may be attributed to the increased
survivin-speciﬁc Th1 type cellular immunity and CTL activity.
Results of clinical cancer studies to date suggest that cancer is difﬁ-
cult to cure with a single treatment, especially with malignant tumors
which have high rates of recurrence and metastasis. Nevertheless, the
combination of immunotherapy with chemotherapy has shown prom-
ise and may open a new avenue in cancer treatment [41]. In our
study, co-administration of the broad-spectrum anti-tumor drug
oxaliplatin and AD-S8/S8 pro could signiﬁcantly enhance the tumor
growth inhibition over that achieved by either treatment alone
(Fig. 6A, B). Furthermore, the proliferation rate of splenocytes from
the AD-S8/S8 pro/Oxa group was remarkably increased (Fig. 6C), con-
sistent with previously described observations by McDonnell et al.
[42]. Overall, combining the use of AD-S8/S8 pro with oxaliplatin
could not only improve the immunogenicity of the vaccine, but also re-
lieve the visible side effects of the chemotherapy drug.
In summary, antigen-speciﬁc cellular responses were effectively in-
duced by using the DDA/MPL adjuvant to enhance the effects of the S8
protein vaccine. Furthermore, two different heterologous prime-boost
immunization regimens could elicit similar levels of T cellular immu-
nity in non-tumor bearing mice. In the murine melanoma model, the
AD-S8/S8 pro vaccine signiﬁcantly decreased the tumor volumes with
no signiﬁcant toxic effects. Moreover, when combined with oxaliplatin,
the AD-S8/S8 pro vaccine more effectively induced cellular immunity
and anti-tumor activity. Taken together, the results indicate that the
AD-S8 prime-S8 pro boost immunization strategy combined with
oxaliplatin may be a potential treatment for melanoma cancer and pro-
vide a novel strategy for survivin-targeted cancer therapy.Acknowledgments
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